Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.

Also called NCT03331289

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose basic science
Phase
Phase 4
Enrolled
  • 107 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03331289
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03331289. Randomized; no masking; primary purpose basic science. Start 2018-02-28 (actual); primary completion 2022-03-31 (actual). Results posted on 2023-07-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
Exenatide
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Exenatide and Dapagliflozin
Lead sponsor
The University of Texas Health Science Center at San Antonio (class: other)
Collaborator
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct03331289
Content hash
f360bb38376229c35b8e3a131de7cc115fcee69226f59b0d2692a54797d71436